Genetic polymorphism of CYP3A5 in Indian chronic myeloid leukemia patients

Molecular and Cellular Biochemistry

Volumn 336, Issue 1-2, 2010, Pages 49-54

  Bajpai, Prachi ^a   Tripathi, Anil Kumar ^b   Agrawal, Deepa ^a  

^a CSIR INDIAN INSTITUTE OF TOXICOLOGY RESEARCH   (India)

^b KING GEORGE'S MEDICAL UNIVERSITY   (India)

Author keywords

Chronic myeloid leukemia; CYPA3A5; Genetic polymorphism

Indexed keywords

CYTOCHROME P450 3A5;

ADULT; AMINO ACID SEQUENCE; CANCER PATIENT; CANCER RISK; CHRONIC MYELOID LEUKEMIA; CONFERENCE PAPER; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; INDIAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK ASSESSMENT;

ADULT; CASE-CONTROL STUDIES; CYTOCHROME P-450 CYP3A; DNA MUTATIONAL ANALYSIS; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; HUMANS; INDIA; LEUKEMIA, MYELOID, CHRONIC-PHASE; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH;

EID: 77649237009     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-009-0268-1     Document Type: Conference Paper

References (40)

1. CL Sawyers 1999 Chronic myeloid leukemia N Engl J Med 340 1330 1340 10.1056/NEJM199904293401706 1:STN:280:DyaK1M3hvFOlug%3D%3D 10219069 (Pubitemid 29196596)
2. WE Evans JA Johnson 2001 Pharmacogenomics: the inherited basis for interindividual differences in drug response Annu Rev Genomics Hum Genet 2 9 39 10.1146/annurev.genom.2.1.9 1:CAS:528:DC%2BD3MXos1antL0%3D 11701642 (Pubitemid 35264999)
3. JR Idle 1991 Is environmental carcinogenesis modulated by host polymorphism? Mutat Res 247 259 266 1:CAS:528:DyaK3MXit1artb0%3D 2011143
4. DR Nelson 1999 Cytochrome P450 and the individuality of species Arch Biochem Biophys 369 1 10 10.1006/abbi.1999.1352 1:CAS:528:DyaK1MXltlygu70%3D 10462435 (Pubitemid 29434533)
5. DR Nelson L Koymans T Kamataki JJ Stegeman R Feyereisen DJ Waxman, et al. 1996 P450 superfamily: update on new sequences, gene mapping, accession numbers, and nomenclature Pharmacogenetics 6 1 41 10.1097/00008571-199602000- 00002 1:CAS:528:DyaK28XisFyhsLg%3D 8845856 (Pubitemid 26096749)
6. T Shimada H Yamazake M Mimura Y Inui FP Guengerich 1994 Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians J Pharmacol Exp Ther 270 414 423 1:CAS:528: DyaK2cXlt1OmtL4%3D 8035341
7. G Smith LA Stanley E Sim RC Strange CR Wolf 1995 Metabolic polymorphisms and cancer susceptibility Cancer Surv 25 27 65 1:CAS:528:DyaK28XitV2mt7s%3D 8718512
8. H Raunio K Husgafvel-Pursianen S Anttila E Hietanen A Hirvonen O Pelkonen 1995 Diagnosis of polymorphisms in carcinogen-activating and inactivating enzymes and cancer susceptibility Gene 159 113 121 10.1016/0378-1119(94)00448-2 1:CAS:528:DyaK2MXmvFWqsrw%3D 7607565
9. DS Sonnichsen Q Liu EG Schuetz JD Schuetz A Pappo MV Relling 1995 Variability in human cytochrome P450 paclitaxel metabolism J Pharmacol Exp Ther 275 566 575 1:CAS:528:DyaK2MXpsF2htbo%3D 7473140
10. S Rendic FJ Di Carlo 1997 Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors Drug Metab Rev 29 413 580 10.3109/03602539709037591 1:CAS:528:DyaK2sXkt1Onur8%3D 9187528
11. RW Estabrook 1996 The remarkable P450s: a historical overview of these versatile hemoprotein catalysts FASEB J 10 202 204 1:STN:280: DyaK283gs1Sksw%3D%3D 8641552
12. SJ Lee KA Usmani B Chanas B Ghanayem T Xi E Hodgson HW Mohrenweiser JA Goldstein 2003 Genetic findings and functional studies of human CYP3A5 single nucleotide polymorphisms in different ethnic groups Pharmacogenetics 13 461 472 10.1097/00008571-200308000-00004 1:CAS:528:DC%2BD3sXlvV2jt7g%3D 12893984 (Pubitemid 37034588)
13. P Kuehl J Zhang Y Lin J Lamba M Assem J Schuetz PB Watkins, et al. 2001 Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression Nat Genet 27 383 391 10.1038/86882 1:CAS:528:DC%2BD3MXjtFShs7k%3D 11279519 (Pubitemid 32268418)
14. C Balram QY Zhou YB Cheung, et al. 2003 CYP3A5, 3 and, 6 single nucleotide polymorphisms in three distinct Asian populations Eur J Clin Pharmacol 59 123 126 1:CAS:528:DC%2BD3sXksFGlu7k%3D 12756511
15. Sambrook J, Russell DW (2001) Molecular cloning: a laboratory manual, 3rd edn. Cold Spring Harbor, NY, Cold Spring Harbor Laboratory
16. TC Liu SF Lin TP Chen JG Chang 2002 Polymorphism analysis of CYP3A5 in myeloid leukemia Oncol Rep 9 327 329 1:CAS:528:DC%2BD38XitVCgsLs%3D 11836601
17. J-N Roy J Lajoie LS Zijenah A Barama C Poirier BJ Ward, et al. 2005 CYP3A5 genetic polymorphisms in different ethnic populations Drug Metab Dispos 33 884 887 10.1124/dmd.105.003822 1:CAS:528:DC%2BD2MXlslWqsrY%3D 15833928 (Pubitemid 41002766)
18. A Hirvonen 1999 Polymorphisms of xenobiotic-metabolizing enzymes and susceptibility to cancer Environ Health Perspect 107 Suppl 1 37 47 10.2307/3434470 1:CAS:528:DyaK1MXit1Wms7s%3D 10229705
19. H Autrup 2000 Genetic polymorphisms in human xenobiotica metabolizing enzymes as susceptibility factors in toxic response Mutat Res 464 65 76 1:CAS:528:DC%2BD3cXjtFSrtw%3D%3D 10633178
20. P Bajpai AK Tripathi D Agrawal 2007 Increased frequencies of glutathione-S-transferase (GSTM1 & GSTT1) null genotypes in Indian patients with chronic myeloid leukemia Leuk Res 31 1359 1363 10.1016/j.leukres.2007.02. 003 1:CAS:528:DC%2BD2sXovFKntL8%3D 17420047 (Pubitemid 47212426)
21. A Hishida S Terakura N Emi K Yamamoto M Murata K Nishio, et al. 2005 GSTT1 and GSTM1 deletions, NQO1 C609T polymorphism and risk of chronic myelogenous leukemia in Japanese Asian Pac J Cancer Prev 6 251 255 16235982
22. BC Mondal N Paria S Majumdar S Chandra A Mukhopadhyay U Chaudhuri, et al. 2005 Glutathione-S-transferase M1 and T1 null genotype frequency in chronic myeloid leukaemia Eur J Cancer Prev 14 281 284 10.1097/00008469-200506000-00014 1:STN:280:DC%2BD2M3mtV2qsA%3D%3D 15901999 (Pubitemid 40780453)
23. JG Lourenco MM Ortega H Nascimento TM Teori AC DeSouza FF Costa, et al. 2005 Polymorphisms of glutathione-S-transferase mu1 (GSTM1) and theta 1 (GSTT1) genes in chronic myeloid leukaemia Eur J Haematol 75 530 531 10.1111/j.1600-0609.2005.00567.x 1:CAS:528:DC%2BD2MXhtlelsL%2FO 16313269 (Pubitemid 41687790)
24. J Bjork M Albin H Welinder H Tinnerberg N Mauritzson T Kauppinen, et al. 2001 Are occupational, hobby, or lifestyle exposures associated with Philadelphia chromosome positive chronic myeloid leukemia? Occup Environ Med 58 722 727 10.1136/oem.58.11.722 1:STN:280:DC%2BD3MrlsVWmtg%3D%3D 11600728 (Pubitemid 33010490)
25. AK Daly 2006 Significance of the minor cytochrome P450 3A isoforms Clin Pharmacokinet 45 13 31 10.2165/00003088-200645010-00002 1:CAS:528: DC%2BD28Xis1ejsbo%3D 16430309 (Pubitemid 43145013)
26. PJ Roberts KD Rollins AD Kashuba MF Paine AC Nelsen EE Williams, et al. 2008 The influence of CYP3A5 genotype on dexamethasone induction of CYP3A activity in African Americans Drug Metab Dispos 36 1465 1469 10.1124/dmd.107.020065 1:CAS:528:DC%2BD1cXptlanurY%3D 18490434
27. E Hustert M Haberl O Burk R Wolbold YQ He K Klein, et al. 2001 The genetic determinants of the CYP3A5 polymorphism Pharmacogenetics 11 773 779 10.1097/00008571-200112000-00005 1:CAS:528:DC%2BD38XnsFKqsrk%3D 11740341 (Pubitemid 33151512)
28. N Bozina V Bradamante M Lovric 2009 Genetic polymorphism of metabolic enzymes P450 (CYP) as a susceptibility factor for drug response, toxicity, and cancer risk Arh Hig Rada Toksikol 60 217 242 1:CAS:528:DC%2BD1MXoslyhu7o%3D 19581216
29. D Anglicheau C Legendre P Beaune E Thervet 2007 Cytochrome P450 3A polymorphisms and immunosuppressive drugs: an update Pharmacogenomics 8 835 849 10.2217/14622416.8.7.835 1:CAS:528:DC%2BD2sXnvVersb4%3D 18240909 (Pubitemid 47288980)
30. S Crettol JP Venetz M Fontana JD Aubert M Pascual CB Eap 2008 CYP3A7, CYP3A5, CYP3A4, and ABCB1 genetic polymorphisms, cyclosporine concentration, and dose requirement in transplant recipients Ther Drug Monit 30 689 699 10.1097/FTD.0b013e31818a2a60 1:CAS:528:DC%2BD1cXhsVKnt73P 18978522
31. S Leskela E Honrado C Montero-Conde I Landa A Cascón R Leton P Talavera JM Cózar A Concha M Robledo C Rodríguez-Antona 2007 Cytochrome P450 3A5 is highly expressed in normal prostate cells but absent in prostate cancer Endocr Relat Cancer 14 645 654 10.1677/ERC-07-0078 1:CAS:528:DC%2BD2sXhsVSisbfL 17914095 (Pubitemid 350074054)
32. DT Petrova N Yaramov S Toshev P Nedeva S Maslyankov N von Ahsen M Oellerich D Toncheva 2007 Genotyping of CYP3A5 polymorphisms among Bulgarian patients with sporadic colorectal cancer and controls Onkologie 30 559 563 10.1159/000108285 1:CAS:528:DC%2BD2sXht1Oks7rJ 17992026 (Pubitemid 350085276)
33. LJ Shen FY Chen T Wang HR Wang JH Zhong JY Han RR Ouyang 2008 Polymorphisms of CYP3A5 gene in acute leukemia patients and their role in chemotherapy and prognosis Zhongguo Shi Yan Xue Ye Xue Za Zhi 1 26 30
34. C Keshava EC McCanlies A Weston 2004 CYP3A4 polymorphisms-potential risk factors for breast and prostate cancer: a HuGE review Am J Epidemiol 160 825 841 10.1093/aje/kwh294 15496535 (Pubitemid 39434767)
35. MH Vaarala H Mattila P Ohtonen TL Tammela TK Paavonen J Schleutker 2008 The interaction of CYP3A5 polymorphisms along the androgen metabolism pathway in prostate cancer Int J Cancer 122 2511 2516 10.1002/ijc.23425 1:CAS:528:DC%2BD1cXltlaiurY%3D 18306354 (Pubitemid 351590484)
36. SJ Plummer DV Conti PL Paris AP Curran G Casey JS Witte 2003 CYP3A4 and CYP3A5 genotypes, haplotypes, and risk of prostate cancer Cancer Epidemiol Biomarkers Prev 12 928 932 1:CAS:528:DC%2BD3sXnsValt7Y%3D 14504207
37. M Jin SB Gock PJ Jannetto JM Jentzen SH Wong 2005 Pharmacogenomics as molecular autopsy for forensic toxicology: genotyping cytochrome P450 3A4, 1B and 3A5, 3 for 25 fentanyl cases J Anal Toxicol 29 590 598 1:CAS:528: DC%2BD2MXhtFChs7fF 16419387
38. Bajpai P, Tripathi AK, Agrawal D (2008) Polymorphism of CYP3A5 gene in Indian chronic myeloid leukemia patients (abstract). In: Proceedings of the frontiers in cancer prevention research, Washington, DC, 16-19 Nov 2008, p 125. Abstract nr B42
39. R Aplenc W Glatfelter P Han, et al. 2003 CYP3A genotypes and treatment response in paediatric acute lymphoblastic leukaemia Br J Haematol 122 240 244 10.1046/j.1365-2141.2003.04430.x 1:CAS:528:DC%2BD3sXmsFGis7s%3D 12846892 (Pubitemid 36859609)
40. JG Blanco MJ Edick ML Hancock, et al. 2002 Genetic polymorph isms in CYP3A5, CYP3A4 and NQO1 in children who developed therapy-related myeloid malignancies Pharmacogenetics 12 605 611 10.1097/00008571-200211000-00004 1:CAS:528:DC%2BD38XovVeitLY%3D 12439220 (Pubitemid 36005669)